The principal psychoactive ingredient in marijuana, ⌬ 9 -tetrahydrocannabinol, has been shown to inhibit adenylyl cyclase activity in vitro and can lead to impairment of memory in vivo. cAMP-induced changes in synaptic plasticity are thought to underlie memory formation. We examined the effects of cannabinoid receptor agonists on forskolin-induced formation of new synapses between rat hippocampal neurons in culture. Functional synaptic boutons were identified with FM1-43-based digital imaging. Cannabimimetic drugs prevented the recruitment of new synapses by inhibiting the formation of cAMP. The inhibition produced by Win55212-2, a synthetic cannabinoid receptor agonist, was stereoselective and was reversed by a selective CB1 receptor antagonist. Both ⌬ 9 -tetrahydrocannabinol and the endogenous ligand, anandamide, inhibited the formation of new synapses. Win55212-2 blocked the formation of new synapses induced by forskolin, but not those evoked by a membrane permeant cAMP analog. Thus, activation of cannabinoid receptors can modulate synaptic plasticity independent of direct effects on neurotransmitter release. Preventing the formation of new synapses may contribute to the impairment of memory produced by cannabinoids.
The cannabinoid CB1 receptor is one of the most abundant G-protein-coupled receptors in the brain (Herkenham et al., 1990) . CB1 receptors couple to inhibitory G-proteins, and, thus, cannabinoid agonists inhibit adenylyl cyclase (Howlett and Fleming, 1984; Howlett et al., 1986) . Activation of CB1 receptors also inhibits synaptic transmission (Shen et al., 1996; Chan et al., 1998; Hoffman and Lupica, 2000; Takahashi and Linden, 2000) , probably via inhibition of voltage-gated Ca 2ϩ channels (Twitchell et al., 1997; Shen and Thayer, 1998; Sullivan, 1999) and activation of K ϩ channels Mackie et al., 1995; Mu et al., 2000) . Cannabimimetic drugs produce a number of behavioral effects (Adams and Martin, 1996; Chaperon and Thiebot, 1999; Pertwee, 2000) , including memory deficits (Heyser et al., 1993; Lichtman et al., 1995; .
The cAMP signaling cascade is central to certain types of learning and memory (Impey et al., 1998) . Changing the strength of connections between neurons is thought to underlie memory formation and may result from the recruitment of new sites of synaptic transmission (Bolshakov et al., 1997) . New functional synapses between hippocampal neurons in culture can be induced by an elevation in cAMP (Kavalali et al., 1999; Ma et al., 1999) .
Because cAMP-induced changes in synaptic plasticity contribute to memory formation and cannabimimetic drugs are known to inhibit adenylyl cyclase and impair memory, we hypothesized that activation of CB1 receptors would modulate cAMP-dependent synaptic plasticity. We used an FM1-43-based assay to identify functional synaptic boutons in rat hippocampal cultures and found that cannabimimetic drugs prevent the recruitment of new synapses by inhibiting the formation of cAMP.
MATERIALS AND METHODS
Materials. Materials were obtained from the following suppliers: FM1-43, Molecular Probes (Eugene, OR); ⌬ 9 -tetrahydrocannabinol (⌬ 9 -THC) and SR141716, National Institute on Drug Abuse Drug Supply System (Bethesda, MD); Win55212-2, tetrodotoxin, and all other reagents, Sigma, (St. L ouis, MO).
Cell culture. Rat hippocampal neurons were grown in culture as described previously (Shen et al., 1996) .
Imag ing synaptic boutons. Functional synaptic boutons were labeled by evoking neurotransmitter release with 60 mM K ϩ for 2 min in the presence of 5 M FM1-43. The cells were washed then for 10 min in buffer containing 300 nM tetrodotoxin, and a fluorescence image was acquired with a cooled CCD camera (576 ϫ 384 pixels) (K im and Thayer, 2000) . The cells were again depolarized (60 mM K ϩ ; 30 sec), and a second image was acquired. A difference image representing releasable FM1-43 was analyzed then with N IH image software (http://rsb.info.nih-.gov/nih-image/). Background was subtracted from the entire image using a two-dimensional rolling ball (10 pixel radius) algorithm, and then the image was smoothed with a Mexican hat filter to detect the edges of structures. To f urther reduce noise, a pixel value 3 SD above the mean of the entire field was subtracted, and f unctional boutons were identified objectively as clusters of at least five pixels.
RESULTS
Cannabinoid CB1 receptors are expressed at high density in the hippocampus (Herkenham et al., 1990; Tsou et al., 1998) , a part of the brain important for learning and memory . Rat hippocampal neurons were grown in tissue culture (Shen et al., 1996) , and the number of functional neurotransmitter release sites was measured with the amphipathic membrane fluorescent dye FM1-43 (Betz and Bewick, 1992; Ma et al., 1999) . Depolarization (60 mM K ϩ ) of hippocampal neurons in the presence of FM1-43 trapped dye within synaptic vesicles during the endocytosis that followed neurotransmitter release. Digital imaging revealed fluorescent puncta that decreased in intensity during a second depolarization because of FM1-43 release after vesicle fusion. Depolarization-induced FM1-43 release required Ca 2ϩ influx through N-and P/Q-type voltage-gated Ca 2ϩ channels as indicated by sensitivity to selective channel toxins (Kim and Thayer, 2000) . Subtracting the image after release from that preceding depolarization produced a difference image that identified functional sites of neurotransmitter release (Fig. 1) .
Forskolin induces formation of new functional synapses
Elevated cAMP will produce long-term changes in the strength of hippocampal synapses requiring protein synthesis (Frey et al., 1993) . Ma et al. (1999) have shown that a brief (15 min) elevation of cAMP will result in an increase in the number of functional synaptic boutons measured 2 hr later. We found that 2 hr after a 15 min treatment with 25 M forskolin, an activator of adenylyl cyclase, the number of FM1-43-labeled sites increased by 37 Ϯ 7% (n ϭ 4) ( Fig. 1 B, C) , a significant increase relative to control experiments (no forskolin) in which the number of FM1-43-labeled sites increased by only 2 Ϯ 4% (Fig. 1 D) . The forskolininduced increase in functional boutons was dependent on the age of the culture. The formation of new synapses peaked at 12 d in vitro and then declined over the next several days. Thus, each experiment was compared with a control performed on the same day. Rp-cAMPS (25 M), an inhibitor of protein kinase A, prevented the forskolin-induced increase in synaptic sites ( Fig.  1 D) , consistent with new synapse formation resulting from a forskolin-induced increase in cAMP. Protein synthesis was required for the induction of new synaptic sites because the proteinsynthesis inhibitor, anisomycin (20 M), blocked their induction (Fig. 1 D) .
Cannabimimetic drugs inhibit forskolin-induced recruitment of functional synaptic boutons
Cannabinoid receptor agonists inhibit long-term potentiation in hippocampus (Stella et al., 1997) . We examined the effects of cannabimimetic drugs on the induction of new synaptic sites. Application of the cannabinoid receptor full agonist Win55212-2 (300 nM) during the 15 min forskolin treatment largely blocked the induction of new synaptic sites (Fig. 2) . This effect was mediated via the CB1 cannabinoid receptor because the addition of the selective antagonist SR141716 (1 M) completely prevented the Win55212-2-induced inhibition. ⌬ 9 -Tetrahydrocannabinol (300 nM) reduced the forskolin-induced increase in synaptic sites by half (18 Ϯ 2% increase), consistent with its action as a partial agonist (Sim et al., 1996b; Shen and Thayer, 1999) . Anandamide (1 M) also inhibited the forskolin-induced increase in FM1-43-labeled sites, suggesting that endogenous cannabinoid signaling may serve to modulate synapse formation (Fig. 2C) . 
Win55212-2 inhibits new synapse formation by inhibiting the formation of cAMP
The induction of new functional boutons in this model of synaptic plasticity requires synaptic activity, although the activation of postsynaptic receptors can be separated temporally from the cAMP-induced initiation of this process. When NMDA-and non-NMDA-type ionotropic glutamate receptors were blocked during the entire experiment with APV and CNQX, respectively, forskolin failed to induce new functional boutons (Fig. 3) . However, blocking postsynaptic glutamate receptors only during the 15 min forskolin application was without effect on the induction of new synaptic sites. Note that when cannabimimetic drugs were given, they were applied during this time. In a previous study, we found that the effects of Win55212-2 washed out within 10 min (Shen et al., 1996) . These data suggest that although activation of presynaptic cannabinoid receptors will inhibit the release of glutamate (Shen et al., 1996) , this was not the mechanism by which these drugs were preventing the formation of new functional boutons. The inhibition of neurotransmitter release by cannabinoids is likely mediated by a membrane-delimited action of inhibitory G-proteins on voltage-gated Ca 2ϩ channels (Herlitze et al., 1996; Twitchell et al., 1997; Shen and Thayer, 1998; Sullivan, 1999) . Because long-term potentiation of hippocampal mossy fiber synapses at CA3 is a cAMP-dependent process (Huang et al., 1994) , we hypothesized that cannabimimetic drugs were preventing new synapse formation by inhibiting the forskolininduced increase in cAMP. Consistent with this idea was the failure of Win55212-2 to inhibit the formation of new synapses induced by application of the membrane permeant cAMP analog, Sp-cAMPS (Fig. 3, shaded bars) .
DISCUSSION
Forskolin increased by 37 Ϯ 7% the number of FM1-43-labeled functional synapses between cultured hippocampal neurons. The formation of new synaptic sites was dependent on activation of protein kinase A and required translation, in good agreement with other studies in which cAMP-dependent increases in functional synapses were studied (Kavalali et al., 1999; Ma et al., 1999; Bozdagi et al., 2000) . The forskolin-induced increase in the number of functional boutons described here is similar to the increase in synaptic puncta induced by Sp-cAMPS in hippocampal slices (Bozdagi et al., 2000) . In contrast, the Sp-cAMPS-induced increase in the number of functional boutons observed by Ma et al. (1999) was considerably larger than that described here and may result from differences in the cell culture preparations.
Cannabimimetic drugs inhibited recruitment of new synapses by activation of CB1 receptors as indicated by antagonism with SR141716. ⌬ 9 -THC inhibited new synapse formation, although by only ϳ50%, consistent with the partial agonist properties of this drug (Sim et al., 1996a; Shen and Thayer, 1999) . Marijuana is known to affect learning and memory in humans (Abel, 1970; Tart, 1970; Chaperon and Thiebot, 1999) and impaired synaptic plasticity may underlie this deficit. Anandamide was also an effective inhibitor of new synapse formation, raising the interest- and presence (solid bars) of cannabimimetic drugs applied during the 15 min treatment with forskolin: 300 nM Win55212-2 (n ϭ 4), 300 nM Win55212-2 and 1 M SR141716 (n ϭ 4), 300 nM ⌬ 9 -THC (n ϭ 4), and 1 M anandamide (n ϭ 4). *p Ͻ 0.05; **p Ͻ 0.01, treatment plus forskolin relative to forskolin alone; paired Student's t test. Error bars represent SEM. ing possibility that the endocannabinoid system may regulate the number of functional synapses. Such regulation might be especially important during learning, development, and chronic stimulation of the nervous system. Win55212-2 blocked the formation of new synaptic boutons induced by forskolin but not those induced by Sp-cAMPS, suggesting that cannabimimetic drugs inhibit new synapse formation by inhibiting the synthesis, not the actions of cAMP. Induction of new synapses required neurotransmission during the 2 hr incubation period, but not during the 15 min forskolin treatment. Because the cannabimimetic drugs were applied only during forskolin treatment, the temporal requirements of the paradigm also argue against blocked synaptic transmission as the mechanism by which these drugs inhibited new synapse formation. It is possible that cannabinoid modulation of both cAMP signaling and neurotransmission contribute to changes in synaptic plasticity in vivo. Functional (Shen et al., 1996) and anatomical (Katona et al., 1999; Irving et al., 2000) data suggest a presynaptic localization of CB1 receptors, and study of hippocampal synapse development suggests that presynaptic boutons assemble before postsynaptic assembly (Friedman et al., 2000) . Thus, cannabinoids may act presynaptically to inhibit new synapse formation. A presynaptic increase in cAMP is required for induction of cerebellar long-term potentiation (LTP) (Linden and Ahn, 1999) , consistent with the idea that modulation of presynaptic adenylyl cyclase will alter the strength of synaptic connections.
Other receptors that couple to adenylyl cyclase may regulate synaptic plasticity by modulating cAMP levels. This is clearly true for G s -coupled receptors such as the ␤ adrenergic receptor, activation of which lowers the threshold for eliciting both the early and the late phase of mossy fiber LTP (Huang and Kandel, 1996) . Activation of adenosine A 1 receptors will inhibit LTP, which could theoretically be mediated via inhibition of adenylyl cyclase, but the strong inhibition of neurotransmitter release by adenosine appears to predominate (de Mendonca and Ribeiro, 1997) . It will be interesting to examine further the role of G i -coupled receptors in models such as that used here, in which modulation cAMPdependent synaptic plasticity can be separated from direct modulation of synaptic transmission.
Recruitment of previously silent synapses contributes to increased synaptic efficacy during the late phase of LTP (Impey et al., 1996; Bolshakov et al., 1997 ). Several reports demonstrate that activation of cannabinoid receptors will inhibit LTP (Stella et al., 1997; Misner and Sullivan, 1999; Bohme et al., 2000) . There is some controversy regarding the precise mechanism by which cannabinoid receptor agonists inhibit LTP, and a link to the cAMP signaling cascade has not been suggested previously. The cell culture model used in this study is difficult to compare with LTP at anatomically defined synapses, although cannabinoid inhibition of synaptic plasticity is a theme common to each of these studies. Indeed, multiple mechanisms may underlie these effects, including reduced neurotransmitter release, inhibited adenylyl cyclase, and possibly more complex network related phenomena. Inhibition of the formation of new functional synapses may account for the effects of cannabinoids on memory , although at present we cannot explicitly link the in vitro effects to the in vivo effects of these drugs. Recruitment of previously silent synapses also occurs during development of synaptic transmission (Dubinsky and Fischbach, 1990; Durand et al., 1996; Liao et al., 1999; Petralia et al., 1999) , and cannabinoids are known to produce defects in neurodevelopment (Dalterio, 1986; Fernandez-Ruiz et al., 2000) . Synaptic plasticity in the spinal cord may contribute to chronic pain (Li and Zhuo, 1998) . Cannabinoids have strong analgesic properties, although longterm changes in synaptic strength have not been implicated in these actions (Walker et al., 1999) .
Cannabinoids inhibited the formation of new synaptic boutons in vitro. This inhibition might contribute to the detrimental effects of these drugs on memory formation. The possibility that endocannabinoids might regulate the number of synapses in vivo suggests a role for cannabinoid signaling in modulating the changes in neuronal communication associated with learning, development, and pain.
